Immix Biopharma, Inc. Banner Image

Immix Biopharma, Inc.

  • Ticker IMMX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Immix Biopharma, Inc. Logo Image
  • 1-10 Employees
  • Based in Los Angeles, California
Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Their lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Their proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificMore Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Their TME Normalization™ Technology allows their drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. They have uncovered fundamental biological systems that link oncology and inflammation. Their pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Immix Biopharma, Inc.

Most Recent Annual Report

Immix Biopharma, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Immix Biopharma, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!